Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry

Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer

(2009) Axel S Merseburger et al.   Expert Review of Anticancer Therapy

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma

(2009) M.P. Sablin et al.   JOURNAL OF UROLOGY

Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib

(2009) Kaja Zimmermann et al.   ONCOLOGY

How Can Second-Line Therapy for Metastatic Renal Cell Carcinoma Help to Define an Overall Management Strategy?

(2009) Bohuslav Melichar   ONCOLOGY

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

(2008) Arkadiusz Z. Dudek et al.   CANCER

Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis

(2008) Christian Eichelberg et al.   EUROPEAN UROLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Antitumor Effects of Sunitinib or Sorafenib in Patients With Metastatic Renal Cell Carcinoma Who Received Prior Antiangiogenic Therapy

(2007) Ila Tamaskar et al.   JOURNAL OF UROLOGY